Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

Abstract

The article discusses various prophylactic options for CMV using different antiviral agents.

Keywords

• chronic lymphocytic leukemia
• valaciclovir
• valganciclovir
• alemtuzumab
• CMV